CJC-1295

CJC-1295 API 

CJC-1295 is a synthetic, tetrasubstituted peptide analogue of growth hormone releasing hormone (GHRH), designed to stimulate and sustain the secretion of endogenous growth hormone (GH). Unlike native GHRH, which has a short half-life, CJC-1295 incorporates a Drug Affinity Complex (DAC) technology, allowing it to bind covalently to albumin in the bloodstream and prolong its biological half-life to over 8 days. This innovation makes CJC-1295 a long-acting GHRH analogue with significant potential in anti-aging, growth deficiency, metabolic regulation, muscle-wasting disorders, and regenerative medicine.

Mechanism of Action

CJC-1295 acts on the GHRH receptor located on somatotropic cells in the anterior pituitary gland. Its biological function mimics that of native GHRH, but with a significantly extended half-life due to the DAC modification. This sustained action enables stable pulsatile release of GH and increased production of insulin-like growth factor 1 (IGF-1).

Key mechanisms include:

• Stimulation of endogenous GH secretion

• Prolonged elevation of IGF-1 levels, supporting anabolic effects

• No significant desensitization or downregulation with continuous use

• Enhanced lipolysis, protein synthesis, and cellular regeneration

By triggering the body’s own GH and IGF-1 pathways, CJC-1295 avoids many of the drawbacks associated with exogenous GH therapy, such as receptor desensitization and safety concerns.

Therapeutic Research and Clinical Potential

1. Growth Hormone Deficiency (GHD)

In early-phase clinical trials, CJC-1295 has demonstrated:

• Sustained increases in GH and IGF-1 levels for up to 6–10 days after a single injection

• Reduced injection frequency compared to daily GHRH analogues or GH injections

• Improved patient compliance and hormonal stability

2. Body Composition and Muscle Preservation

Animal and human studies have shown that CJC-1295:

• Promotes lean muscle gain and reduces body fat, particularly visceral fat

• Enhances nitrogen retention and protein synthesis in skeletal muscle

• May aid in recovery from sarcopenia and muscle-wasting conditions

3. Anti-Aging and Wellness Applications

As GH and IGF-1 levels naturally decline with age, CJC-1295 is increasingly studied as an anti-aging intervention to:

• Improve sleep quality and circadian rhythm regulation

• Enhance skin elasticity, bone density, and immune function

• Support energy metabolism and fatigue resistance

4. Metabolic Regulation

CJC-1295 shows promise in addressing insulin resistance and metabolic syndrome by:

• Improving glucose utilization

• Enhancing lipid oxidation and adipose tissue metabolism

• Supporting weight management in obese or pre-diabetic individuals

API Manufacturing and Quality Control

At Gentolex Group, our CJC-1295 API is produced using solid-phase peptide synthesis (SPPS) and purified using HPLC to achieve high purity and batch-to-batch consistency.

Key Specifications:

• Purity ≥ 99% (HPLC confirmed)

• Low residual solvents and heavy metals

• Endotoxin-free, non-immunogenic synthesis route

• Available in custom quantities: milligram to kilogram scale

Applications and Future Potential

CJC-1295 is considered one of the most promising long-acting GHRH analogues, with potential applications in:

• Adult GH deficiency therapy

• Body composition management in obesity and aging

• Rehabilitation from muscle loss or trauma

• Performance and recovery enhancement in clinical or sports settings

• Supportive therapy in chronic fatigue, fibromyalgia, and neuroendocrine imbalance

Ongoing clinical trials are exploring its use as an alternative to recombinant GH, particularly in populations seeking safer, more physiological hormone modulation.